The aggregate repurchase authorization program now totals $200 million, which the firm will fund with cash and cash equivalents.
The firm said that investors provided better-than-expected backing as the company anticipates growing use of its digital pathology platform in 2025.
The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback